Summary
The provided FDA label excerpts support Onglyza’s indication and mechanism-of-action, but the prompt does not supply FDA label text for non-medical claims (marketing company, patent expiration/generics/pricing/market effects). Therefore, most claims cannot be verified against the provided label excerpts, and the audit cannot be completed reliably for those items.
Category Scores
Accurate Statements
Onglyza (saxagliptin) is a medication used to treat type 2 diabetes.
Label excerpt under INDICATIONS AND USAGE/1.1: ONGLYZA is indicated to improve glycemic control in adults with type 2 diabetes mellitus.
Onglyza works by improving the body's response to insulin.
Label excerpt 12.1 Mechanism of Action: saxagliptin increases incretin concentrations leading to glucose-dependent insulin secretion; and lowers glucagon, reducing hepatic glucose production (net effect on glycemic control).
Unsupported Statements
Onglyza works by increasing the production of insulin in the body.
Label supports increased glucose-dependent insulin secretion from pancreatic beta cells (mechanism), but the claim is phrased as general 'increasing production of insulin' without the glucose-dependent/incretin-mediated context. Provided excerpt does not literally state 'production of insulin' language.
Onglyza is marketed by AstraZeneca.
No FDA label excerpt provided about marketing company.
The patent on Onglyza is set to expire in 2023.
No FDA label excerpt provided about patent status/expiration dates.
Generic manufacturers will be able to produce their own versions of Onglyza after the patent expiration.
No FDA label excerpt provided about patent/generic manufacturing permissions.
Generic versions of Onglyza are expected to increase competition in the market.
No FDA label excerpt provided about market competition.
The launch of generic Onglyza is likely to have a significant impact on pricing.
No FDA label excerpt provided about pricing/market effects.
Prices of Onglyza are expected to decrease after the launch of generic Onglyza.
No FDA label excerpt provided about pricing changes.
The average wholesale price of Onglyza is currently around $4.50 per pill.
No FDA label excerpt provided about wholesale price or cost.
Generic manufacturers are expected to offer their versions of Onglyza at a significantly lower price point.
No FDA label excerpt provided about generic pricing.
The launch of generic Onglyza is likely to increase patients' access to the medication due to lower prices.
No FDA label excerpt provided about access or economic impact.
Lower prices from the generic Onglyza launch are expected to improve patients' quality of life.
No FDA label excerpt provided about quality of life or economic-driven patient outcomes.
Increased competition in the market due to generic Onglyza may lead to more innovative treatments and therapies being developed.
No FDA label excerpt provided about market competition driving innovation.
The launch of generic Onglyza is likely to impact healthcare providers by allowing them to offer the medication at a lower cost due to lower prices.
No FDA label excerpt provided about provider cost impact.
Lower cost access to Onglyza through the generic launch is expected to reduce healthcare costs.
No FDA label excerpt provided about healthcare cost outcomes.
Lower cost access through the generic launch is expected to improve patient outcomes.
No FDA label excerpt provided about patient outcomes driven by pricing/access.
Contradictions
Important Omissions
FDA label excerpts for non-medical claims (e.g., marketing company, patent expiration, generic availability, pricing/market impacts) were not provided, so verification against the label is not possible for those items.
Importance:
High
The audit request includes no verbatim label sections for BOXED WARNINGS, CONTRAINDICATIONS, WARNINGS/PRECAUTIONS, DOSAGE AND ADMINISTRATION, DRUG INTERACTIONS, or USE IN SPECIFIC POPULATIONS to evaluate relevant safety or administration claims (if any were made).
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Low
The only clinically relevant claims provided relate to indication and general mechanism; the economically/market/pricing claims are unsupported by the provided FDA label excerpts but do not directly assert dosing, contraindications, or safety management.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
High |
Recommendation
Mostly Misaligned
Primary Issue
Most claims (marketing company, patent expiration, generics, pricing/market effects, access/QoL/cost/outcomes) are not supported by the provided FDA label excerpts and therefore cannot be validated against prescribing information.
Suggested Improvement
Limit label-derivable statements to the FDA-indicated use and label-described mechanism (with glucose-dependent/incretin-mediated wording as provided), and omit or clearly qualify market/pricing/patent/access predictions that are not contained in the prescribing information excerpts.